Prostate Health Index Density Outperforms PSA Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal MRI Prostates: A Multicenter Evaluation

Peter Ka-Fung Chiu,Chih-Hung Chiang,Kai Zhang,Po-Fan Hsieh,Yao Zhu,Wayne Lam,Woon-Chau Tsang,Yu-Hua Fan,Tzu-Ping Lin,Tsz-Yeung Chan,Chi-Ho Leung,Jeremy Yen-Chun Teoh,Peggy Sau-Kwan Chu,Gang Zhu,Ding-Wei Ye,Hsi-Chin Wu,Teck-Wei Tan,James Hok-Leung Tsu,Chi-Fai Ng,Edmund Chiong,Chao-Yuan Huang,Jeffrey J. Leow,Alex Mok

DOI: https://doi.org/10.1097/ju.0000000000003450

2023-04-10

Abstract:PURPOSE: We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy.MATERIALS AND METHODS: This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy performed and without prior prostate cancer diagnosis were included. The additional value of PSA density, Prostate Health Index, and Prostate Health Index density to MRI Prostate Imaging Reporting & Data System score was evaluated with multivariable analyses, area under the curve, and decision curve analyses. The proportion of unnecessary biopsies that can be avoided are estimated for clinically significant prostate cancer (International Society of Urological Pathology group ≥2 prostate cancer).RESULTS: A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prostate cancer was diagnosed in 4.4% (3/68), 15% (72/470), 39% (176/446), and 74% (171/231) of highest Prostate Imaging Reporting & Data System score of 2, 3, 4, and 5 lesions, respectively. In multivariable analyses, independent predictors for clinically significant prostate cancer detection included Prostate Health Index (OR 1.04), prostate volume (OR 0.97), and Prostate Imaging Reporting & Data System score 4 (OR 2.81) and 5 (OR 8.34). Area under the curve for clinically significant prostate cancer of Prostate Imaging Reporting & Data System + Prostate Health Index density (0.85) was superior to Prostate Imaging Reporting & Data System + PSA density (0.81), Prostate Health Index density (0.81), Prostate Health Index (0.78), Prostate Imaging Reporting & Data System (0.76), PSA density (0.72), and PSA (0.60) in the whole cohort, and the superiority of Prostate Health Index density was also observed in Prostate Imaging Reporting & Data System 3 lesions. Decision curve analysis showed Prostate Health Index density achieving the best net clinical benefit in Prostate Imaging Reporting & Data System 3 or 4 cases. Among Prostate Imaging Reporting & Data System 3 lesions, using cutoffs of PSA density 0.15, Prostate Health Index 38.0, and Prostate Health Index density 0.83 could reduce 58%, 67%, and 72% of unnecessary biopsies, respectively.CONCLUSIONS: Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnecessary biopsies in Prostate Imaging Reporting & Data System 3 lesions.

urology & nephrology